Teleflex $TFXRead from its own SEC filings · nothing written, nothing inferred
🫧 Edgar looked up TELEFLEX INCORPORATED ($TFX). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-09-09. 19 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $2.0B (FY2025), total debt $2.6B. Experience: revenue up 17.2% on the year, down 8.2% a year over 4 years; operating margin 5.9%, down from 6.1%. Soundness: equity 45.0% of assets, return on equity -29.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.5B and $2.8B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.2B to $3.5B. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 5.9% against a 1.2% median; growth 17.2% against 11.6%.
Next year, 80%$1.5B–$2.8B
Growth, on the year17.2%
Operating margin5.9%
Equity of assets45.0%
Credibility50%
Track record12 of 14
TELEFLEX INCORPORATED against its own record and its peersHanded back now, or kept to compound · of each dollar of profit
Gold paid out, navy kept. Kept share × return on equity = the growth it can fund itself. Facts from the filings, not a recommendation.
Speed and cash · fiscal 2025
Cash flow (op · inv · fin · free)
— · −$813M · $612M · —
Investment book (cash · short · long)
$379M · — · — · current ratio 2.54
Revenue swing · equity of assets
28.0% · 45.0%
Teleflex is growing slower than its size class, with revenue that swings more. Its own audited SEC figures.
The figures, as filed
Fiscal year end
2025-12-31
Revenue
$2.0B
Revenue, on the year
17.2%
Revenue, a year over the record
−8.2%
Operating margin
5.9%
Operating margin, prior year
6.1%
Net margin
−45.4%
Research and development
$145M · 7.3% of revenue
Total debt
$2.6B
Equity of assets
45.0%
Return on equity
−29.0%
Payout of profit
—
Dividend per share
$1.36
Earnings per share
$-20.3
Book value per share
$69.87
Revenue per share
$44.56
Shares outstanding
44,724,000
Audited years read
5
Peers: the median of 60 filers with $50M+ revenue in surgical & medical instruments & apparatus.
filed restructuring or exit costs in the last 12 months
slow and jumpy: growing slower than its size class, with revenue that swings more
revenue is hard to predict: its 80% range is ±30%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
Recent filings
8-K · 2026-09-09 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
8-K · 2026-08-06 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
8-K · 2026-08-03 · 2.01 Completion of Acquisition or Disposition of Assets; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
8-K · 2026-06-15 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company
1 · Watch
Tell me when they file
Or tap watch on any row above. One note the day they file, from Edgar, each with a one-click stop link. Handled to EU GDPR and Japan APPI standards.
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked
Clean data. No ads. Not now, not later.
Nine boards reading every SEC filing the day it lands, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.
Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.